Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 27:12:9-15.
doi: 10.33393/grhta.2025.3199. eCollection 2025 Jan-Dec.

Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA)

María Reyes Abad  1 , Carmen Alerany  2 , Luis Ignacio González  3 , Olaf Neth  4 , Concepción Payares-Herrera  5 , Carlos Rodríguez-Gallego  6 , Jose Luis Trillo  7 , Kirsten H Herrmann  8 , Raquel Figueiredo  9 , Alicia Gil  10
Affiliations

Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA)

María Reyes Abad et al. Glob Reg Health Technol Assess. .

Abstract

Background: Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS) is an ultra-rare, potentially life-threatening disease that lacks approved treatments in Spain. This study aimed to apply Multi-Criteria Decision Analysis (MCDA) to assess the value of the first pharmacological treatment for APDS in Spain.

Methods: A multidisciplinary group of 8 experts evaluated the selective PI3Kδ inhibitor leniolisib against Standard of Care (SoC). An MCDA framework tailored for Orphan Drugs (ODs), consisting of 5 comparative and 2 quantitative non-comparative criteria, was used. Re-scoring followed a group discussion.

Results: Leniolisib scored higher than SoC in all criteria, including efficacy and safety. It was deemed highly valuable as the first disease-modifying treatment, with a positive therapeutic impact and potential to improve patients' quality of life. Additionally, leniolisib may lead to cost savings. The supporting data was considered of high quality.

Conclusion: Based on MCDA methodology and stakeholder experience in APDS management, leniolisib is seen as a value-added treatment option compared to SoC in Spain.

Keywords: Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS); Decision-making; Multi-criteria Decision Analysis (MCDA); Ultra-rare disease; leniolisib.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: RA, CA, LIG, AH, ON, CP, CR-G, and JLT have received honoraria from Pharming for their participation in this study. KHH and RF are employees of Pharming. AG is an employee of Omakase Consulting, which received funding from Pharming for the development and performance of this study and the elaboration of the manuscript. None of the authors have received honoraria for the review of the manuscript.

Figures

FIGURE 1 -
FIGURE 1 -
Flowchart of the literature review.
FIGURE 2 -
FIGURE 2 -
Scoring results – Quantitative comparative criteria.
FIGURE 3 -
FIGURE 3 -
Scoring results – Qualitative non-comparative criteria.
FIGURE 4 -
FIGURE 4 -
Value contribution of leniolisib by expert profile.
See this image and copyright information in PMC

References

    1. Angulo I, Vadas O, Garçon F et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. 2014;342(6160):866, 71. - PMC - PubMed
    1. Lucas CL, Kuehn HS, Zhao F et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88–97. doi: 10.1038/ni.2771. - DOI - PMC - PubMed
    1. Lucas CL, Zhang Y, Venida A et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med. 2014;211(13):2537–2547. doi: 10.1084/jem.20141759. - DOI - PMC - PubMed
    1. Deau MC, Heurtier L, Frange P et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. 2014;124(9):3923–3928. doi: 10.1172/JCI75746. - DOI - PMC - PubMed
    1. Orphanet: Síndrome de PI3K delta activado. [Accessed July; 2024 ]; Online

LinkOut - more resources